stockrowIovance Biotherapeutics, Inc.
IOVA Healthcare Biotechnology
Iovance Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $263.5 million, up 60.6% from fiscal 2024.
- Revenue
- +80.1%
- EPS
- +80.0%
- Free cash flow
- +89.7%
Quarter to September 2026, against a year earlier
Follow IOVA
Alert me
Iovance Biotherapeutics, Inc. (IOVA) Return on invested capital
Iovance Biotherapeutics, Inc.'s return on invested capital over the twelve months to 30 September 2026 was −17.7%, up 45.0 percentage points from fiscal 2025 (−62.8%). Over the past ten years it has ranged from −53,748.3% (fiscal 2017) to 0.00% (fiscal 2019); the current reading is higher than 82% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −62.8% | 0.96 |
| FY2024 | −63.7% | 30.42 |
| FY2023 | −94.2% | 771.68 |
| FY2022 | −865.8% | (684.70) |
| FY2021 | −181.1% | 423.84 |
| FY2020 | −605.0% | (604.97) |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | 53,748.26 |
| FY2017 | −53,748.3% | (46,265.14) |
| FY2016 | −7,483.1% | (2,092.25) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | 18.6% |
| RLAY Relay Therapeutics, Inc. compare | 0.00% |
| IRON Disc Medicine, Inc. compare | 0.00% |
| EWTX Edgewise Therapeutics, Inc. compare | 0.00% |
| PBLS Parabilis Medicines, Inc. compare | 0.00% |
| IOVA Iovance Biotherapeutics, Inc. | −17.7% |
| ABCL AbCellera Biologics Inc. compare | −42.5% |
| XENE Xenon Pharmaceuticals Inc. compare | −88.5% |
| TNGX Tango Therapeutics, Inc. compare | −808.4% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on IOVA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement